单酰甘油脂肪酶
化学
丝氨酸水解酶
内大麻素系统
神经炎症
药理学
丝氨酸
生物化学
酶
炎症
内科学
受体
医学
作者
Laura A. McAllister,Christopher R. Butler,Scot Mente,Steven V. O’Neil,Kari R. Fonseca,Justin R. Piro,Julie Cianfrogna,Timothy L. Foley,Adam M. Gilbert,Anthony R. Harris,Christopher J. Helal,Douglas S. Johnson,Justin I. Montgomery,Deane M. Nason,Stephen Noell,Jayvardhan Pandit,Bruce N. Rogers,Tarek A. Samad,Christopher L. Shaffer,Rafael G. da Silva,Daniel P. Uccello,Damien Webb,Michael A. Brodney
标识
DOI:10.1021/acs.jmedchem.8b00070
摘要
Monoacylglycerol lipase (MAGL) inhibition provides a potential treatment approach to neuroinflammation through modulation of both the endocannabinoid pathway and arachidonoyl signaling in the central nervous system (CNS). Herein we report the discovery of compound 15 (PF-06795071), a potent and selective covalent MAGL inhibitor, featuring a novel trifluoromethyl glycol leaving group that confers significant physicochemical property improvements as compared with earlier inhibitor series with more lipophilic leaving groups. The design strategy focused on identifying an optimized leaving group that delivers MAGL potency, serine hydrolase selectivity, and CNS exposure while simultaneously reducing log D, improving solubility, and minimizing chemical lability. Compound 15 achieves excellent CNS exposure, extended 2-AG elevation effect in vivo, and decreased brain inflammatory markers in response to an inflammatory challenge.
科研通智能强力驱动
Strongly Powered by AbleSci AI